Enhanced, the company behind the Enhanced Games, has launched an online personalised performance medicine and supplement platform and said it plans to expand further into peptides. The initial rollout includes proprietary supplement blends, hormone replacement therapy for men and women, and other longevity-focused protocols.
That matters because this is not just a product extension. It is a vertical integration move. Enhanced is attempting to turn a controversial sports property into a consumer health and performance brand, using the visibility of the Games to support a direct-to-consumer commerce business. Gizmodo reported that the company plans to market five peptides through its new online health service, with ambitions to add more if regulation loosens.
Peptide products and compounded performance medicine
The core technology here is not a new sensor or device. It is a platform built around compounded therapies, performance protocols, and personalised product selection.
Enhanced said its current platform already offers Sermorelin and plans to add Tesamorelin, Glutathione, and Oxytocin, while potentially expanding into additional compounds such as CJC-1295, Ipamorelin, Thymosin Alpha-1, TB-4, GHRP-2/6, Kisspeptin-10, Semax, and Selank if regulatory conditions allow. The company tied that expansion to possible movement of 14 peptide compounds from the FDA’s Category 2 restricted list to Category 1, which would again allow licensed 503A pharmacies to compound them.
Performance medicine platforms are consumer health businesses built around therapies, supplements, and protocols designed to optimise recovery, body composition, hormonal function, or perceived longevity through personalised treatment pathways.
What is a performance medicine platform?
A performance medicine platform is a digital health commerce model that combines clinical protocols, compounded therapies, supplements, and personalised guidance to sell optimisation-focused interventions for energy, recovery, body composition, or longevity. In practice, it sits somewhere between telehealth, biohacking retail, and consumer wellness infrastructure.
Why the peptide category matters now
Enhanced said the global peptide therapeutics market is worth about $52 billion today and could reach $87 billion by 2035. That gives the company a clear commercial rationale for expansion.
But the larger signal is strategic. Peptides have historically sat in a grey zone between clinical medicine, compounding, underground biohacking, and online “research chemical” culture. Gizmodo notes that many of the compounds Enhanced wants to sell remain controversial, and that some were previously described by the FDA as posing potentially significant safety risks. The article also notes that Kennedy had spoken publicly about loosening restrictions on 14 peptides.
That combination — regulatory ambiguity, consumer demand, and ideological support for optimisation — is creating an opening for new health brands to position themselves as trusted gateways into a previously fragmented market.
Sports spectacle is becoming a distribution engine for health products
The most important industry signal is the merger of two models: sports entertainment and performance medicine retail.
Enhanced’s CEO said the company’s athlete clinical trial data informs its consumer strategy and helps position the brand around “longevity and performance needs.” The company is also sponsoring an IRB-approved trial involving 40 elite athletes connected to the inaugural Enhanced Games event in Las Vegas on May 24, 2026.
That suggests a broader pattern. Health and performance brands increasingly want more than audience attention. They want proprietary data, owned distribution, and a direct commercial path from spectacle to product purchase.
Future implications for consumer biohacking and longevity commerce
Over the next five to ten years, this model could reshape parts of the optimisation economy in three ways.
First, performance medicine may become a branded consumer category, not just a niche clinical service. Second, sports and athlete narratives may become acquisition channels for longevity products. Third, regulatory shifts around compounding and peptides may determine which companies scale fastest.
Enhanced’s update is therefore about more than peptides. It signals a future in which performance brands do not just sponsor aspiration. They sell the protocols, compounds, and clinical pathways attached to it.
